VivoSeq
Cardiovascular

Chagas Cardiomyopathy

8

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Chagas cardiomyopathy is an early-stage landscape with 8 programs across 3 companies. The most active players are Eastern Cooperative Oncology Group, Teva, Novartis. 2 therapies are approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

75/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

Eastern Cooperative Oncology Group

1 program

Phase 3Teva logo

Teva

1 program

Phase 3Novartis logo

Novartis

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

89%

Small molecule

8 of 9 classified programs — the dominant modality here.

11%ALL OTHERSProtein / enzyme111%

Small molecule leads; the ring shows all 9 classified programs, each share of the total. Modality classified for 100% of 9 pipeline programs.

Analysis

Trial Status

7

clinical trials

Completed3 · 43%
Recruiting2 · 29%
Terminated1 · 14%
Unknown status1 · 14%

Clinical Trials

Trial Activity

7 trials

Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: ANSWER-HF.
Recruiting·UUniversity of Sao Paulo General Hospital·Phase 3·NCT04853758·200 enrolled
Clinical and Functional Effects of Cardiac Contractility Modulation in Chagas Heart Disease: a Randomized Study - Contractility - FIX-Chagas
Recruiting·IInCor Heart Institute·Preclinical·NCT05519046·60 enrolled
Chagas Cardiomyopathy Bisoprolol Intervention Study: Charity
Completed·FFundación Cardiovascular de Colombia·Phase 3·NCT00323973·500 enrolled
A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy
Completed·FFederal University of Minas Gerais·Phase 4·NCT01557140·42 enrolled
Evaluation of G-CSF (Colony Stimulating Factor) in Patients With Chronic Chagas Cardiomyopathy
Completed·HHospital Sao Rafael·Phase 2·NCT02154269·70 enrolled
Cell Therapy in Chagas Cardiomyopathy
Terminated·Ministry of Health, Brazil·Phase 3·NCT00349271·182 enrolled
Amiodarone Against ICD Therapy in Chagas Cardiomyopathy for Primary Prevention of Death
Unknown status·IInCor Heart Institute·N/A·NCT01722942·1,100 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)